Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
CML
•
Hematology
Do you recommend antimicrobial prophylaxis in patients with CML blast crisis after 7+3 induction while on maintenance TKI awaiting allo transplant?
Related Questions
What are the treatment options for relapsed T-ALL in a patient who was nonadherent with AALL and hyper-CVAD regimens?
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?
What is your approach to treatment of relapsed, high-risk MDS with TP53 mutation in a patient that is not considered a transplant candidate?
Does treating CLL reduce the risk of non-melanoma skin cancers?
How long do you continue ursodiol for VOD prophylaxis after gemtuzumab ozogamicin for good-risk AML
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
What factors do you consider when choosing between asciminib vs TKI in a newly diagnosed CML patient?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?
